Literature DB >> 18392753

Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study.

Pascal Goetghebeur1, Rebecca Dias.   

Abstract

RATIONALE: Selective cognitive impairments, including those of executive function as assessed using the Wisconsin Card Sort Test or intradimensional-extradimensional (ID-ED) tests, are a key feature of schizophrenia but remain inadequately treated by existing therapies. Recently, however, modafinil has been shown to improve attentional set-shifting performance in patients with schizophrenia.
OBJECTIVE: The present study evaluated the recently described analogous rat ID-ED attentional set-shifting task by investigating the effects of various pharmacological challenges to a phencyclidine (PCP)-induced ED shift impairment, namely, haloperidol, risperidone, sertindole, and modafinil.
MATERIALS AND METHODS: Rats were subjected to a subchronic systemic administration of either saline vehicle or PCP (5 mg/kg i.p. b.i.d. for 7 days) followed by a 7-day washout period. During this period, rats were trained to dig in baited bowls for a food reward and to discriminate based on odor or digging media. In a single test session conducted the day after the washout period (day 8), rats performed a series of discriminations following acute administration of either vehicle, or haloperidol (0.1 mg/kg s.c.), or risperidone (0.2 mg/kg i.p.), or sertindole (1.25 mg/kg p.o.) or modafinil (64 mg/kg p.o.).
RESULTS: The subchronic PCP-induced ED deficit was ameliorated by sertindole and modafinil but not by haloperidol or risperidone.
CONCLUSIONS: Overall, these findings further support that the rat ID-ED test in subchronic PCP-treated rats has utility and validity as a preclinical model of the cognitive symptoms of schizophrenia and demonstrates back-translational potential.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18392753     DOI: 10.1007/s00213-008-1132-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  53 in total

1.  Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability.

Authors:  M D S Lapiz; D A Morilak
Journal:  Neuroscience       Date:  2005-11-17       Impact factor: 3.590

2.  Primate analogue of the Wisconsin Card Sorting Test: effects of excitotoxic lesions of the prefrontal cortex in the marmoset.

Authors:  R Dias; T W Robbins; A C Roberts
Journal:  Behav Neurosci       Date:  1996-10       Impact factor: 1.912

3.  The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.

Authors:  Sophie Rémillard; Emmanuelle Pourcher; Henri Cohen
Journal:  Schizophr Res       Date:  2005-09-12       Impact factor: 4.939

4.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

5.  Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex.

Authors:  Paul J Fletcher; Catherine C Tenn; Zoë Rizos; Vedran Lovic; Shitij Kapur
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

6.  Clozapine, SCH 23390 and alpha-flupenthixol but not haloperidol attenuate acute phencyclidine-induced disruption of conditional discrimination performance.

Authors:  Michael J Dunn; Simon Killcross
Journal:  Psychopharmacology (Berl)       Date:  2007-01-20       Impact factor: 4.530

7.  Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.

Authors:  E M Tunbridge; D M Bannerman; T Sharp; P J Harrison
Journal:  J Neurosci       Date:  2004-06-09       Impact factor: 6.167

8.  Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man.

Authors:  A M Owen; A C Roberts; C E Polkey; B J Sahakian; T W Robbins
Journal:  Neuropsychologia       Date:  1991       Impact factor: 3.139

9.  The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

Authors:  T E Goldberg; R D Greenberg; S J Griffin; J M Gold; J E Kleinman; D Pickar; S C Schulz; D R Weinberger
Journal:  Br J Psychiatry       Date:  1993-01       Impact factor: 9.319

10.  Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.

Authors:  Michael Didriksen; Torben Skarsfeldt; Jørn Arnt
Journal:  Psychopharmacology (Berl)       Date:  2007-04-04       Impact factor: 4.415

View more
  37 in total

Review 1.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

2.  Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.

Authors:  Segev Barak; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

3.  Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat.

Authors:  Philip L R Gaskin; Stephen P H Alexander; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 4.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

Review 5.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity.

Authors:  Neil Dawson; Rhiannon J Thompson; Allan McVie; David M Thomson; Brian J Morris; Judith A Pratt
Journal:  Schizophr Bull       Date:  2010-09-01       Impact factor: 9.306

Review 7.  Emerging treatments in the management of schizophrenia - focus on sertindole.

Authors:  Maria Rosaria A Muscatello; Antonio Bruno; Gianluca Pandolfo; Umberto Micò; Salvatore Settineri; Rocco Zoccali
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

8.  Emerging role of sertindole in the management of schizophrenia.

Authors:  Stephanie L Cincotta; Joshua S Rodefer
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

9.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

10.  Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.

Authors:  Brian Villumsen Broberg; Birte Yding Glenthøj; Rebecca Dias; Dorrit Bjerg Larsen; Christina Kurre Olsen
Journal:  Psychopharmacology (Berl)       Date:  2009-04-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.